China Approves World's First Invasive Brain Implant
Chinese regulators have granted approval for the world's first invasive brain-computer interface (BCI) chip. Strong government support is expected to accelerate the country's transformation into a global leader in neuroimplants.
Playing Ahead: How China Won the Regulatory Race, Not the Technology Race, in BCI
[The Gist]: What's Really Happening
When in March 2026 China's NMPA granted commercial approval for the invasive brain implant NEO from Neuracle Technology, the world hailed it as a "Chinese breakthrough." But those inside the industry understand: this is not a victory of engineers over biology—it's a victory of bureaucracy over risks. China didn't win the technology race; it won the regulatory race.
The traditional "space race" metaphor, picked up by global media, doesn't fully apply here. MIT Technology Review points this out, quoting researcher Meisen Sun: the US aims for "extraordinariness"—being first to create the most advanced technology. China, on the other hand, targets "accessibility"—a scalable solution for the mass market. These are two fundamentally different games.
But there's a deeper, less obvious layer. The NMPA decision is not just an "approval." It's a political signal sent not so much to the world as to the domestic market. The Chinese government included BCI in its list of six key future industries in the 15th Five-Year Plan. The approval of NEO came on the same day the plan was published. Coincidence? In China, such coincidences don't happen. It's a synchronized strike: regulation and industrial policy work as a single fist, pushing open the "iron curtain" for clinical trials.
Timeline and Context
To understand how Neuracle outpaced Neuralink, look at the numbers. Neuralink today has about three to four dozen implanted patients, if Musk is to be believed. Neuracle has 36 clinical trials, 32 of which were conducted in 2025. The pace of building a clinical base for the Chinese company is several times higher. This was made possible by an "accelerated regulatory pathway"—China's FDA equivalent works like a race car, not a sand truck.
But the key point most analysts miss: NEO is technologically less ambitious than Neuralink's N1. NEO is a semi-invasive implant. Its sensors sit on the dura mater, without penetrating the cerebral cortex. This is a deliberate choice: to reduce the risk of hemorrhage, glial scarring, and long-term signal degradation. Neuralink, on the other hand, goes for maximum invasion—ultra-thin threads penetrate directly into the cortex to read signals with maximum resolution.
China's strategy here resembles Toyota's approach to hybrid cars in the late 1990s: not the most powerful, not the fastest, but the most reliable and ready for mass production. And the result was immediate. Patient Dong Hui, paralyzed after an accident, could squeeze a ball without a robotic glove on the ninth day of training. By the 11th month, he could write by hand. It works.
Who Wins and Who Loses
The first and obvious winner is Neuracle and its scientific partner, Tsinghua University. The company has gained a unique "window of opportunity": exclusive access to the Chinese market with a product already included in the medical insurance system (NEO received a unique insurance code). This means the government will subsidize implantation for eligible patients. Demand is artificially created, but no less real for it.
The second, less visible winner is Axoft, a US company from Cambridge, Massachusetts. It has partnered with a Chinese company and a hospital in Shanghai to test its implants on four patients in China. In a climate where US-China cooperation in semiconductors and AI is virtually frozen, neurotechnology has become a rare "green corridor." Axoft gets access to China's clinical base, and China gets access to cutting-edge US developments. It's a quiet deal that mainstream media ignores.
The main loser is not Neuralink. Neuralink remains the technology leader in signal resolution and ambition (the "full brain" project by 2028). The loser is Synchron, an Australian-American company with Stentrode technology, which is inserted via the jugular vein. Synchron has for years bet on "minimally invasive" as its main competitive advantage. Now the Chinese offer the same concept ("placement on the dura mater") with comparable or better bandwidth and already have commercial approval and insurance. Synchron's investment appeal in the next funding round could be seriously damaged.
What the Media Isn't Saying
The main unspoken factor that changes the whole picture is NEO's vulnerability to peripheral attacks. Everyone talks about the chip. But they forget about the surgical robotic system for implantation. Neuralink developed its own robot for ultra-precise thread implantation. Neuracle has no such system in open sources. The NEO implantation surgery is a standard neurosurgical procedure requiring a highly skilled surgeon. And here China faces a bottleneck: the number of neurosurgeons capable of performing such operations is in the hundreds, while potential patients number in the hundreds of thousands. Scaling will hit the ceiling of human capital. Neuralink, by automating the process, solves this problem at its root.
The second unspoken factor is language. NEO was trained on Chinese. NeuroXess, another Chinese player, already demonstrates decoding of Mandarin at 300 characters per minute, faster than average native speech. This is a phenomenal achievement, but it raises the question: will NEO work with tonal languages as well as with English? If the neural network decoder architecture is tailored to the logic of Chinese, exporting the technology to the West will require complete retraining of models. This creates a natural "technological sovereignty": China gets a BCI that works optimally with a Chinese brain speaking Chinese. Neuralink was developed for global English. This is a subtle but fundamental difference that foreshadows a fragmentation of the BCI market along linguistic lines.
Forecast: Next 30 Days and 90 Days
Next 30 days.
Within the next month, an avalanche of applications from Chinese patients with spinal cord injuries will begin. The NMPA approved NEO for patients aged 18-60 with tetraplegia (paralysis of all four limbs) but with preserved residual hand function. This is a relatively narrow window, but even within it, there are tens of thousands of potential users. Expect Neuracle to announce the first "commercial" (not clinical) implantation within 30 days. This will be a major PR event with state media involvement.
At the same time, a buying spree of Chinese BCI company stocks on the A-share market will begin. In January 2026, after Neuralink's mass production announcement, nearly 40 Chinese BCI stocks rose more than 10% in a single day. Now the effect will be even stronger, because this is not an announcement but real approval. Watch companies from IT桔子 reports—they will get a new influx of capital.
Next 90 days.
By the end of the third month after approval, an event will occur that changes the entire landscape of global BCI investment. With high probability (I estimate 70%), Neuracle will announce a partnership with one of the "big three" Chinese insurance companies (Ping An, China Life, PICC). Insurance will become the driver of mass adoption: patients will pay not $30,000-50,000 for the device (expert estimate), but only 10-20% of that amount. This will make BCI in China more affordable than anywhere else in the world and force the FDA and European regulators to sharply accelerate their processes to remain competitive.
Also within the 90-day horizon, expect a submission for approval of "Beinao-1" from the Chinese Institute for Brain Research in Beijing. If the NMPA approves it too—and I predict this will happen faster than Avinash Singh expects (he says 2028, but I bet on late 2026 to early 2027)—we will see the formation of an oligopoly of three to four state-affiliated BCI companies in China. These will be Neuracle, Beinao, NeuroXess, and possibly StairMed. The market will be divided not by competition but by administrative principle: each company will take its niche (hand rehabilitation, speech restoration, cursor control).
And a final insight that goes unspoken. In response to China's approval, Neuralink may announce a shift in its commercial release timeline from 2027 to the fourth quarter of 2026. This would be a desperate move, because their technology is objectively more complex and requires more time for safety validation. But geopolitical pressure could force Musk to go all-in. If that happens, expect the first fatal accident in BCI history within 12 months of the rushed launch. China, by choosing a more conservative path, may not only be first but also the only one not to stumble on this minefield.
— Editorial Team
No comments yet.